PT101297A - Factores mitogenicos gliais, sua preparacao e utilizacao - Google Patents

Factores mitogenicos gliais, sua preparacao e utilizacao

Info

Publication number
PT101297A
PT101297A PT101297A PT10129793A PT101297A PT 101297 A PT101297 A PT 101297A PT 101297 A PT101297 A PT 101297A PT 10129793 A PT10129793 A PT 10129793A PT 101297 A PT101297 A PT 101297A
Authority
PT
Portugal
Prior art keywords
glitary
utilization
preparation
mitogenic factors
mitogenic
Prior art date
Application number
PT101297A
Other languages
English (en)
Other versions
PT101297B (pt
Inventor
Andrew David John Goodearl
Michael Derek Waterfield
Paul Stroobant
Luisa Minghetti
Mark Andrew Marchionni
Original Assignee
Ludwig Inst Cancer Res
Cambridge Neuroscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Inst Cancer Res, Cambridge Neuroscience Inc filed Critical Ludwig Inst Cancer Res
Publication of PT101297A publication Critical patent/PT101297A/pt
Publication of PT101297B publication Critical patent/PT101297B/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity
    • C07K14/4705—Regulators; Modulating activity stimulating, promoting or activating activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/82—Translation products from oncogenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus
PT101297A 1992-06-30 1993-06-30 Polipeptideos que sao factores de crescimento mitogenicos para celulas da glia, sequencias de dna que os codificam e aplicacao terapeutica destes polipeptideos PT101297B (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US90713892A 1992-06-30 1992-06-30
US94038992A 1992-09-03 1992-09-03
US96517392A 1992-10-23 1992-10-23
US08/036,555 US5530109A (en) 1991-04-10 1993-03-24 DNA encoding glial mitogenic factors

Publications (2)

Publication Number Publication Date
PT101297A true PT101297A (pt) 1994-06-30
PT101297B PT101297B (pt) 1999-10-29

Family

ID=27488375

Family Applications (1)

Application Number Title Priority Date Filing Date
PT101297A PT101297B (pt) 1992-06-30 1993-06-30 Polipeptideos que sao factores de crescimento mitogenicos para celulas da glia, sequencias de dna que os codificam e aplicacao terapeutica destes polipeptideos

Country Status (11)

Country Link
US (8) US5530109A (pt)
EP (1) EP0653940B1 (pt)
JP (1) JP4127567B2 (pt)
KR (2) KR100307943B1 (pt)
AT (1) ATE286126T1 (pt)
AU (2) AU688270B2 (pt)
CA (1) CA2139136A1 (pt)
DE (1) DE69333731T2 (pt)
ES (1) ES2236686T3 (pt)
PT (1) PT101297B (pt)
WO (1) WO1994000140A1 (pt)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050106666A1 (en) * 1991-04-10 2005-05-19 Cambridge Neuroscience Glial mitogenic factors, their preparation and use
US5716930A (en) * 1991-04-10 1998-02-10 Ludwig Institute For Cancer Research Glial growth factors
US7319019B1 (en) * 1991-04-10 2008-01-15 Acorda Therapeutics, Inc. Glial mitogenic factors lacking an N-terminal signal sequence
US5530109A (en) * 1991-04-10 1996-06-25 Ludwig Institute For Cancer Research DNA encoding glial mitogenic factors
US7115554B1 (en) * 1993-05-06 2006-10-03 Acorda Therapeutics, Inc. Methods of increasing myotube formation or survival or muscle cell mitogenesis differentiation or survival using neuregulin GGF III
US7037888B1 (en) * 1992-04-03 2006-05-02 Acorda Therapeutics, Inc. Methods for treating muscle diseases and disorders
US6087323A (en) * 1992-04-03 2000-07-11 Cambridge Neuroscience, Inc. Use of neuregulins as modulators of cellular communication
WO1994003644A1 (en) * 1992-08-10 1994-02-17 Cambridge Neuroscience, Inc. Inhibitors of cell proliferation, their preparation and use
US5770567A (en) * 1994-11-14 1998-06-23 Genentech, Inc. Sensory and motor neuron derived factor (SMDF)
US6750196B1 (en) 1995-03-27 2004-06-15 Acorda Therapeutics Methods of treating disorders of the eye
US5670342A (en) * 1995-04-06 1997-09-23 Amgen Inc. NDF peptides
US5721139A (en) * 1995-05-10 1998-02-24 Genentech, Inc. Isolating and culturing schwann cells
US5849585A (en) * 1995-05-10 1998-12-15 Genetech, Inc. Isolating and culturing Schwann cells
US6033660A (en) * 1995-05-10 2000-03-07 Genentech, Inc. Method of treating a nervous system injury with cultured schwann cells
GB9514325D0 (en) 1995-07-13 1995-09-13 Royal Free Hosp School Med Detection and quantification of human herpes virus 7 by enzymic amplification
US5912326A (en) * 1995-09-08 1999-06-15 President And Fellows Of Harvard College Cerebellum-derived growth factors
JP4382879B2 (ja) 1996-07-12 2009-12-16 ジェネンテック・インコーポレーテッド ガンマ―ヘレグリン
DE69740038D1 (pt) 1996-07-12 2010-12-16 Genentech Inc
US5955111A (en) * 1996-10-08 1999-09-21 Hartford Hospital Methods and compositions for inducing production of stress proteins
US6136558A (en) * 1997-02-10 2000-10-24 Genentech, Inc. Heregulin variants
US6387638B1 (en) 1997-02-10 2002-05-14 Genentech, Inc. Heregulin variants
KR20010031103A (ko) * 1997-10-14 2001-04-16 버틀러 그레고리 비. 네우레굴린을 사용하는 치료요법적 방법
WO1999031505A1 (en) * 1997-12-15 1999-06-24 Shire Laboratories Inc. Neurotrophic factor assay
US20010023241A1 (en) 1998-02-04 2001-09-20 Sliwkowski Mark X. Use of heregulin as a growth factor
US6110718A (en) 1998-03-20 2000-08-29 Wayne State University Mammalian putative phosphatidylinositol-4-phosphate-5-kinase
US6051401A (en) * 1998-07-28 2000-04-18 Bayer Corporation Methods and constructs for protein expression
AUPP785098A0 (en) * 1998-12-21 1999-01-21 Victor Chang Cardiac Research Institute, The Treatment of heart disease
US6635249B1 (en) 1999-04-23 2003-10-21 Cenes Pharmaceuticals, Inc. Methods for treating congestive heart failure
US6933122B1 (en) * 1999-05-14 2005-08-23 The Trustees Of Columbia University In The City Of New York A-form of cytoplasmic domain of nARIA (CRD-neuregulin) and uses thereof
DE50108670D1 (de) 2000-02-11 2006-04-06 Proteosys Ag Verwendung von neuregulin-beta als indikator und/oder target
AU4951501A (en) * 2000-03-27 2001-10-08 Genetics Inst Methods for purifying highly anionic proteins
ES2610353T3 (es) * 2000-05-23 2017-04-27 Cenes Pharmaceuticals, Inc. Moléculas de ácido nucleico NRG-2, polipéptidos y métodos diagnósticos y terapéuticos
EP1417230A2 (en) * 2001-08-06 2004-05-12 ProteoSys AG Neuregulin-beta isoforms associated with neuronal processes
WO2003099320A1 (en) 2002-05-24 2003-12-04 Zensun (Shanghai) Sci-Tech.Ltd Neuregulin based methods and compositions for treating viral myocarditis and dilated cardiomyopathy
EP1660628A4 (en) * 2003-08-19 2010-03-31 Agos Biotech Ltd ERBB LIGAND SPLICE VARIANTS, COMPOSITIONS AND USES THEREOF
TWI276685B (en) * 2003-12-30 2007-03-21 Ind Tech Res Inst Conditional medium for culturing Schwann cells
MX2007002122A (es) * 2004-08-27 2007-10-02 Absorbent Technologies Inc Polimeros superabsorbentes en aplicaciones agricolas.
KR100680479B1 (ko) * 2005-04-11 2007-02-08 주식회사 하이닉스반도체 비휘발성 메모리 장치의 프로그램 검증 방법
US20070213264A1 (en) 2005-12-02 2007-09-13 Mingdong Zhou Neuregulin variants and methods of screening and using thereof
EP2918283B1 (en) 2005-12-30 2018-01-31 Zensun (Shanghai) Science & Technology, Co., Ltd. Extended release of neuregulin for improved cardiac function
US9580515B2 (en) * 2006-08-21 2017-02-28 Zensun (Shanghai) Science & Technology, Co., Ltd. Neukinase, a downstream protein of neuregulin
US7521535B2 (en) * 2006-09-20 2009-04-21 The Board Of Regents For Oklahoma State University Anti-microbial defensin-related peptides and methods of use
US8628929B2 (en) 2007-05-10 2014-01-14 Acorda Therapeutics, Inc. Methods for detecting cardiac damage
US20090156488A1 (en) * 2007-09-12 2009-06-18 Zensun (Shanghai) Science & Technology Limited Use of neuregulin for organ preservation
CN101903036A (zh) * 2007-11-16 2010-12-01 普罗迪奥塞斯股份公司 经翻译后修饰的有活性的可溶性神经调节蛋白亚型
CA2717193C (en) 2008-02-29 2022-08-16 Acorda Therapeutics, Inc. Method for achieving desired glial growth factor 2 plasma levels
US8882700B2 (en) 2008-05-02 2014-11-11 Baxter International Inc. Smart patient transfer set for peritoneal dialysis
US9348975B2 (en) * 2008-05-02 2016-05-24 Baxter International Inc. Optimizing therapy outcomes for peritoneal dialysis
US8057679B2 (en) 2008-07-09 2011-11-15 Baxter International Inc. Dialysis system having trending and alert generation
JP5797112B2 (ja) 2008-07-17 2015-10-21 アコーダ セラピューティクス インコーポレイテッド 心不全の治療または予防のためのニューレグリンまたはそのサブ配列の治療的投与方法
CN104707130A (zh) 2008-08-15 2015-06-17 阿索尔达治疗公司 在cns神经性损伤后非-急性期间处理的组合物及方法
US8609620B2 (en) 2008-11-28 2013-12-17 Zensun (Shanghai) Science & Technology Ltd. Neuregulin peptides and their use
JP2012509908A (ja) * 2008-11-28 2012-04-26 ゼンサン （シャンハイ） サイエンス アンド テクノロジー リミテッド ニューレグリン及び心臓幹細胞
US8377012B2 (en) 2009-01-30 2013-02-19 Baxter International Inc. Transfer sets for therapy optimization
US8282829B2 (en) 2009-05-20 2012-10-09 Baxter International Inc. System and method for automated data collection of twenty-four hour ultrafiltration and other patient parameters using wired or wireless technology
EP2440236B1 (en) 2009-06-09 2016-05-04 Zensun (Shanghai) Science and Technology Limited Neuregulin based methods for treating heart failure
JP2013503110A (ja) 2009-06-09 2013-01-31 ゼンサン （シャンハイ） サイエンス アンド テクノロジー リミテッド ニューレグリンに基づく心不全の治療方法
JP6096262B2 (ja) 2009-08-25 2017-03-15 ゼンサン （シャンハイ） サイエンス アンド テクノロジー，シーオー．，エルティーディー． ニューレグリンに基づく心不全の治療方法
AU2010306777C1 (en) * 2009-10-14 2016-03-17 Acorda Therapeutics, Inc. Use of a neuregulin to treat peripheral nerve injury
US9020827B2 (en) * 2009-10-16 2015-04-28 Baxter International Inc. Peritoneal dialysis optimized using a patient hand-held scanning device
CN102139095A (zh) 2010-01-29 2011-08-03 上海泽生科技开发有限公司 神经调节蛋白用于预防、治疗或延迟心脏缺血再灌注损伤的方法和组合物
WO2013053076A1 (en) 2011-10-10 2013-04-18 Zensun （Shanghai）Science & Technology Limited Compositions and methods for treating heart failure
BR112014024308B1 (pt) 2012-03-30 2021-11-30 Acorda Therapeutics, Inc Uso de neuregulina para tratar lesão de nervo periférico
AU2012392119B2 (en) 2012-10-08 2018-07-26 Zensun (Shanghai) Science & Technology, Co. Ltd. Compositions and methods for treating heart failure in diabetic patients
WO2014138502A1 (en) 2013-03-06 2014-09-12 Acorda Therapeutics, Inc. Therapeutic dosing of a neuregulin or a fragment thereof for treatment or prophylaxis of heart failure
KR102578135B1 (ko) 2013-05-22 2023-09-13 젠순 (상하이) 사이언스 앤드 테크놀로지 캄파니 리미티드 심부전을 치료하기 위한 뉴레귤린의 연장 방출
CN104758922A (zh) 2014-01-03 2015-07-08 上海泽生科技开发有限公司 纽兰格林制剂的配方
WO2015140351A1 (en) 2014-03-21 2015-09-24 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods and pharmaceutical compositions for enhancing myelination
CN105497876B (zh) 2014-09-24 2021-01-15 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延迟心脏室性心律失常的方法和组合物
CN105561298A (zh) 2014-10-17 2016-05-11 上海泽生科技开发有限公司 神经调节蛋白用于预防、治疗或延迟射血分数保留的心力衰竭的方法和组合物
AU2016327974A1 (en) 2015-09-25 2018-04-12 Douglas B. Sawyer Methods for treating cardiac injury
EP3774859B1 (en) 2018-04-11 2024-03-13 Salubris Biotherapeutics, Inc. Human neuregulin-1 (nrg-1) recombinant fusion protein compositions and methods of use thereof
CN111407881A (zh) 2019-01-07 2020-07-14 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延迟心肌损伤的方法和组合物
AR121035A1 (es) 2019-04-01 2022-04-13 Lilly Co Eli Compuestos de neuregulina-4 y métodos de uso
CA3157354A1 (en) 2019-09-16 2021-03-25 Zensun (Shanghai) Science & Technology, Co., Ltd. Recombinant human neuregulin derivatives and use thereof
CN113289002A (zh) 2020-02-24 2021-08-24 上海泽生科技开发股份有限公司 神经调节蛋白用于预防、治疗或延缓心力衰竭的方法和组合物
AR126114A1 (es) 2021-06-10 2023-09-13 Amgen Inc VARIANTES GENOMODIFICADAS DE LA NRG-1 CON UNA SELECTIVIDAD MEJORADA FRENTE AL ErbB4 PERO NO FRENTE AL ErbB3
TW202400217A (zh) 2022-03-15 2024-01-01 美商信立泰生物醫藥公司 用神經調節蛋白－１融合蛋白治療纖維化及心律不整的方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4935341A (en) * 1986-06-04 1990-06-19 Whitehead Institute For Biomedical Research Detection of point mutations in neu genes
US5214034A (en) * 1986-09-26 1993-05-25 Mitsui Toatsu Chemicals, Incorporated Catechol derivatives, and preventive and remedial preparations for regressive disorders in the central nervous system containing the same
US5019559A (en) * 1986-11-14 1991-05-28 President And Fellows Of Harvard College Wound healing using PDGF and IGF-II
US4968603A (en) * 1986-12-31 1990-11-06 The Regents Of The University Of California Determination of status in neoplastic disease
WO1989006692A1 (en) * 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US5057494A (en) * 1988-08-03 1991-10-15 Ethicon, Inc. Method for preventing tissue damage after an ischemic episode
DK0474727T3 (da) * 1989-05-19 1998-01-12 Genentech Inc HER2 ekstracellulært domæne
US5235043A (en) * 1990-04-06 1993-08-10 Synergen, Inc. Production of biologically active, recombinant members of the ngf/bdnf family of neurotrophic proteins
WO1991015230A1 (en) * 1990-04-06 1991-10-17 The Trustees Of The University Of Pennsylvania Ligand for the neu gene product
WO1991018921A1 (en) * 1990-05-25 1991-12-12 Georgetown University GROWTH FACTOR WHICH INHIBITS THE GROWTH OF CELLS OVEREXPRESSING THE HUMAN ONCOGENE erbB-2
US5202428A (en) * 1990-06-20 1993-04-13 The Salk Institute For Biological Studies DNA encoding neurotropic growth factor
EP0574414B1 (en) * 1991-01-14 1999-07-14 Georgetown University LIGAND GROWTH FACTORS THAT BIND TO THE erbB-2 RECEPTOR PROTEIN AND INDUCE CELLULAR RESPONSES
US5530109A (en) * 1991-04-10 1996-06-25 Ludwig Institute For Cancer Research DNA encoding glial mitogenic factors
GB9107566D0 (en) * 1991-04-10 1991-05-29 Ludwig Inst Cancer Res Glial mitogenic factors,their preparation and use
IL101943A0 (en) * 1991-05-24 1992-12-30 Genentech Inc Structure,production and use of heregulin
US5367060A (en) * 1991-05-24 1994-11-22 Genentech, Inc. Structure, production and use of heregulin
US5237056A (en) * 1991-05-29 1993-08-17 President And Fellows Of Harvard College DNA encoding a protein which copurifies with acetylcholine receptor inducing activity and uses therefor
DE69328091T2 (de) * 1992-04-29 2000-10-12 Georgetown University Washingt Bindungspeptide zur interaktion mit wachstumsfaktoren als liganden des rezeptors des epidermiswachstumsfactor und des erbb-2-rezeptor
MX9302475A (es) * 1992-04-29 1994-05-31 Amgen Inc Polipeptido de origen no natural que tiene la actividad del factor recombinante de estimulacion del receptor neu y proceso para la produccion del mis mo.

Also Published As

Publication number Publication date
US6147190A (en) 2000-11-14
US5854220A (en) 1998-12-29
WO1994000140A1 (en) 1994-01-06
PT101297B (pt) 1999-10-29
KR100344006B1 (ko) 2002-12-11
US5602096A (en) 1997-02-11
EP0653940A4 (en) 1997-02-26
ATE286126T1 (de) 2005-01-15
AU4833897A (en) 1998-04-23
US6232286B1 (en) 2001-05-15
DE69333731D1 (de) 2005-02-03
JP4127567B2 (ja) 2008-07-30
US5530109A (en) 1996-06-25
US5621081A (en) 1997-04-15
US5606032A (en) 1997-02-25
JPH08509357A (ja) 1996-10-08
US5792849A (en) 1998-08-11
AU4769493A (en) 1994-01-24
CA2139136A1 (en) 1994-01-06
EP0653940B1 (en) 2004-12-29
ES2236686T3 (es) 2005-07-16
AU688270B2 (en) 1998-03-12
KR100307943B1 (ko) 2001-12-01
EP0653940A1 (en) 1995-05-24
DE69333731T2 (de) 2006-03-09

Similar Documents

Publication Publication Date Title
PT101297A (pt) Factores mitogenicos gliais, sua preparacao e utilizacao
DE69738586D1 (de) Hohe expressionsrate von proteinen
ATE182901T1 (de) Für androgen-rezeptor-protein kodierende dna
ATE310015T1 (de) Hohe expressionsrate des grün-fluoreszierenden proteins
PT93910A (pt) Prodesso para a preparacao de uma proteina heterologa mediante secrecao a partir de uma celula
MD430C2 (ro) Procedeu de obţinere a interferonelor leucocitare umane
DE69022559D1 (de) Expression des rekombinanten Tumor-Nekrosisfaktor-Bindungsproteins I (TBP-I).
HUP9900050A1 (hu) Rekombináns adenovírusok, és felhasználásuk adeno-asszociált vírusok (AAV) előállítására, komplementáló sejtvonalak, és az illető adenovírusokat tartalmazó gyógyszerkészítmények
ATE284954T1 (de) Hyaluronan synthase gen und seine verwendung
NO990086L (no) Avkortete, l°selige tumornekrosefaktorreseptorer av type I og type II
EP0559769A4 (en) Heparin binding mitogen with homology to epidermal growth factor (egf)
DK0601154T3 (da) BPC-peptider, deres fremstilling og anvendelse
WO1997026322A3 (en) Methods and compositions for inhibiting hexokinase
ES8706827A1 (es) Procedimiento para preparar polipeptidos.
FI961202A (fi) Grb3-3-geeni, sen variantteja ja niiden käyttöjä
DE19781038T1 (de) Keratinozytenwachstumsfaktor-2-Produkte
DK0939769T3 (da) Vertebrat-Smoothened-proteiner
SE9602822D0 (sv) New receptor
ATE271125T1 (de) Neuartige tyrosinkinase
FR2744730B1 (fr) Nouvelle famille de canaux potassium de mammifere, leur clonage et leur utilisation notamment pour le criblage de drogues
DE69831231D1 (de) Modulatoren von intrazellulären entzündungs-, zelltod- und zellüberlebenswegen, die card- und kinase-domänen enthalten
DK0643719T3 (da) Nukleinsyresekvenser, som koder for eller er komplementære til nukleinsyresekvenser, som koder for interleukin 9-receptor
PT870015E (pt) Novas xilanases os genes que as codificam e as suas utilizacoes
HUP9801062A2 (hu) Új PKA-kötődő fehérjék, és ezek alkalmazása
SE9604439D0 (sv) New receptor

Legal Events

Date Code Title Description
BB1A Laying open of patent application

Effective date: 19931203

FG3A Patent granted, date of granting

Effective date: 19990707

MM3A Annulment or lapse

Free format text: LAPSE DUE TO NON-PAYMENT OF FEES

Effective date: 20050107

NF3A Restitutio in integrum

Effective date: 20050720

MM4A Annulment/lapse due to non-payment of fees, searched and examined patent

Free format text: MAXIMUM VALIDITY LIMIT REACHED

Effective date: 20140707